Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 10:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Clinical Solutions Clear all
Recruiting No phase listed Observational

BOdygUardian MOnitoriNg for ReCurrencE of AF

NCT07671677
View directory record Official record
Conditions
Atrial Fibrillation (AF)
Interventions
BodyGuardian
Device
Lead sponsor
Heart Rhythm Clinical and Research Solutions, LLC
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Delray Beach, Florida • Miami, Florida • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 25, 2026, 10:59 PM EDT
Completed Phase 2 Interventional

Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary.

NCT00002167
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Tin ethyl etiopurpurin
Drug
Lead sponsor
Clinical Solutions
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 25, 2026, 10:59 PM EDT
Completed No phase listed Observational

Concomitant LAAC/AF Ablation (Watchman FLX Pro)

NCT07041125
View directory record Official record
Conditions
PFA Ablation and LAAC Procedures
Interventions
Watchman FLX™ Pro device.
Device
Lead sponsor
Heart Rhythm Clinical and Research Solutions, LLC
Other
Eligibility
18 Years and older
Enrollment
122 participants
Timeline
2025 – 2026
U.S. locations
15
States / cities
Birmingham, Alabama • San Francisco, California • Littleton, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 25, 2026, 10:59 PM EDT
Terminated No phase listed Observational

Real-World Evidence Registry to Assess Outcomes of Catheter Ablation for Atrial Fibrillation (DYNAMIC AF Registry)

NCT05242250
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Catheter Ablation
Device
Lead sponsor
Heart Rhythm Clinical and Research Solutions, LLC
Other
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Birmingham, Alabama • Annapolis, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Sep 25, 2026, 10:59 PM EDT
Terminated Phase 2 Interventional Results available

Maintaining Suppression of Testosterone With Transdermal Estradiol Gel

NCT02349386
View directory record Official record
Conditions
Cancer of the Prostate
Interventions
BHR-200 (0.36% transdermal 17β-estradiol gel), Placebo
Drug
Lead sponsor
BHR Pharma, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
Tucson, Arizona • Aventura, Florida • Daytona Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Sep 25, 2026, 10:59 PM EDT
Recruiting No phase listed Observational

Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias

NCT04088071
View directory record Official record
Conditions
Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation, Ventricular Arrhythmia
Interventions
Catheter ablation
Device
Lead sponsor
Heart Rhythm Clinical and Research Solutions, LLC
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
71
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 25, 2026, 10:59 PM EDT
Completed Phase 2 Interventional Results available

Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib

NCT01593254
View directory record Official record
Conditions
Chronic Phase Chronic Myeloid Leukemia
Interventions
Imatinib, Dasatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
21
States / cities
Anaheim, California • Fontana, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 25, 2026, 10:59 PM EDT
Recruiting Not applicable Interventional

A Prospective Clinical Study to Evaluate the Effectiveness and Safety of Xcell Amnio MatrixTM (XAM) in the Management of Chronic Non-healing DFUs

NCT07116174
View directory record Official record
Conditions
Diabetic Foot Ulcer (DFU)
Interventions
Xcell Amnio Matrix, Standard of Care (SOC)
Biological · Drug
Lead sponsor
New Horizon Medical Solutions
Network
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Fresno, California • San Diego, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 25, 2026, 10:59 PM EDT
Completed Not applicable Interventional

A Single-Use Duodenoscope in a Real-World Setting

NCT04628949
View directory record Official record
Conditions
Endoscopic Retrograde Cholangiopancreatography (ERCP)
Interventions
aScope™ Duodeno endoscope and aBox™ Duodeno
Device
Lead sponsor
Ambu A/S
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Birmingham, Alabama • Aurora, Colorado • Oak Lawn, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2022 · Synced Sep 25, 2026, 10:59 PM EDT
Completed No phase listed Observational

AI Powered Mapping Technology for Identifying Arrhythmias

NCT06939478
View directory record Official record
Conditions
Arrhythmias, Cardiac
Interventions
Arrhythmia Mapping
Device
Lead sponsor
Heart Rhythm Clinical and Research Solutions, LLC
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Birmingham, Alabama • Jacksonville, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 25, 2026, 10:59 PM EDT
Completed Not applicable Interventional

SoundBite™ Crossing System Pivotal Peripheral CTO Crossing Study

NCT03266835
View directory record Official record
Conditions
Chronic Total Occlusion of Arteries of the Extremities
Interventions
SoundBite™ Crossing System - Peripheral
Device
Lead sponsor
SoundBite Medical Solutions, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Sep 25, 2026, 10:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety and Tolerability Study of RJX Drug Product in Healthy Participants

NCT03680105
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
RJX, Placebo
Drug
Lead sponsor
Reven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2020 · Synced Sep 25, 2026, 10:59 PM EDT
Completed Phase 2 Interventional Results available

Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma

NCT05188729
View directory record Official record
Conditions
Basal Cell Carcinoma, Skin Cancer, Cancer of the Skin, Basal Cell, Cancer of the Skin, Carcinoma
Interventions
Part 1: VP-315 3 Day Dosing/Week, Part 2: VP-315 3 Day Dosing/Week - Loading Dose, Part 2: VP-315 3 Day Dosing/Week - No Loading Dose, Part 2: VP-315 2 Day Dosing/Week - Split Dose, Part 2: VP-315 3 Day Dosing/Week - Split Dose
Drug
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
13
States / cities
San Diego, California • Boca Raton, Florida • Coral Springs, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Sep 25, 2026, 10:59 PM EDT
Completed Not applicable Interventional Results available

Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term

NCT02697916
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
aspirin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
15,076 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
40
States / cities
Los Angeles, California • Wilmington, Delaware • Gainesville, Florida + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Sep 25, 2026, 10:59 PM EDT
Terminated Not applicable Interventional

Safety and Efficacy Study of the SoundBite™ Crossing System With ACTIVE Wire in Coronary CTOs.

NCT03521804
View directory record Official record
Conditions
Chronic Total Occlusion of Coronary Artery
Interventions
SoundBite™ Crossing System Active Wire 14
Device
Lead sponsor
SoundBite Medical Solutions, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Sep 25, 2026, 10:59 PM EDT
Active, not recruiting No phase listed Observational

Real-world Safety and Effectiveness Registry of Catheter Ablation of Paroxysmal Atrial Fibrillation as Initial Control Therapy With the Thermocool SmartTouch SF Catheter (A Sub-study of REAL AF Registry)

NCT07092774
View directory record Official record
Conditions
Paroxysmal Atrial Fibrillation (PAF)
Interventions
Ablation
Device
Lead sponsor
Heart Rhythm Clinical and Research Solutions, LLC
Other
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
12
States / cities
Birmingham, Alabama • Ventura, California • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 25, 2026, 10:59 PM EDT
Completed No phase listed Observational

Safety and Efficacy of Workflows of High Volume Single Operators in a LAAO Device Implant Procedural Day

NCT06436924
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Left Atrial Appendage Device Implant
Device
Lead sponsor
Heart Rhythm Clinical and Research Solutions, LLC
Other
Eligibility
18 Years and older
Enrollment
569 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
7
States / cities
Birmingham, Alabama • Tucson, Arizona • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 25, 2026, 10:59 PM EDT
Completed No phase listed Observational

A Pilot, Proof-of-concept Cohort Study of the Prevalence of Comorbid Mental Illness and Substance Abuse

NCT02476877
View directory record Official record
Conditions
Schizophrenia, Drug Abuse, Anxiety Disorder, Bipolar Disorder, Major Depression
Interventions
Not listed
Lead sponsor
Advanced Clinical Laboratory Solutions, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Sep 25, 2026, 10:59 PM EDT
Completed Phase 2 Interventional Results available

Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP)

NCT03029247
View directory record Official record
Conditions
Anaemia
Interventions
Daprodustat, Epoetin alfa
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
11
States / cities
La Mesa, California • Lakewood, Colorado • Coral Gables, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Sep 25, 2026, 10:59 PM EDT
Completed Not applicable Interventional

HeRO Vascular Access Device Bacteremia Study

NCT00889564
View directory record Official record
Conditions
Hemodialysis
Interventions
HeRO Vascular Access Device
Device
Lead sponsor
Merit Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
Miami, Florida • Atlanta, Georgia • Springfield, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Sep 25, 2026, 10:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Cardiac Effects of ALXN1840 in Healthy Adults

NCT04560816
View directory record Official record
Conditions
Healthy
Interventions
ALXN1840, Placebo, Moxifloxacin
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 25, 2026, 10:59 PM EDT
Terminated Phase 3 Interventional Results available

An Upcoming Clinical Study to Measure the Safety and Impact of a Drug Called Macitentan in Teenage and Adult Fontan Patients.

NCT03775421
View directory record Official record
Conditions
Congenital Heart Disease With Fontan Circulation
Interventions
macitentan 10 mg
Drug
Lead sponsor
Actelion
Industry
Eligibility
12 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Sep 25, 2026, 10:59 PM EDT
Terminated Phase 2 Interventional Results available

A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

NCT03714815
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease
Interventions
macitentan 10 mg
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
11
States / cities
Littleton, Colorado • Chicago, Illinois • Iowa City, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 25, 2026, 10:59 PM EDT
Completed Phase 1 Interventional

Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal Disease

NCT01840956
View directory record Official record
Conditions
End-stage Renal Disease, Kidney Failure, Chronic
Interventions
HAVG
Biological
Lead sponsor
Humacyte, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Durham, North Carolina • Houston, Texas • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Sep 25, 2026, 10:59 PM EDT